AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11072147 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA + BT (intraarterial high-dose-rate brachytherapy)
Number of subjects: 113
Study 11072147 — intervention group
Group type: COMPARATOR
Intervention: PTA (percutaneous transluminal angioplasty)
Number of subjects: 113
Study 11072147 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA + BT
Number of subjects: 113
Study 11072147 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 113
Study 9704176 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus postoperative radiotherapy
Number of subjects: 35
Study 9704176 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy alone
Number of subjects: 35
Study 8006845 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnets
Number of subjects: 36
Study 8006845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 36
Study 8006845 — intervention group
Group type: COMPARATOR
Intervention: Straight bars with clips (control)
Number of subjects: 36
Study 2805828 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent lidocaine (Xylocaine 4 percent topical)
Number of subjects: 20
Study 2805828 — intervention group
Group type: COMPARATOR
Intervention: 4 percent lidocaine (commercial preparation)
Number of subjects: 20
Study 2805828 — intervention group
Group type: COMPARATOR
Intervention: 4 percent preservative-free lidocaine solution
Number of subjects: 20
Study 766822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 175
Study 766822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 31691605 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (10U/kg/leg)
Number of subjects: 241
Study 31691605 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (15U/kg/leg)
Number of subjects: 241
Study 31691605 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (open-label phase)
Number of subjects: 241
Study 31691605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 31272823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 3004
Study 31272823 — intervention group
Group type: COMPARATOR
Intervention: Intubation
Number of subjects: 3004
Study 28610668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (detailed dosage not specified)
Number of subjects: 711
Study 28610668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 711
Study 27326444 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 27326444 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 23435530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 0
Study 23435530 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 0
Study 23435530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate/Folic acid
Number of subjects: 0
Study 23435530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21256803 — intervention group
Group type: EXPERIMENTAL
Intervention: ramelteon 8 mg
Number of subjects: 987
Study 21256803 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 987
Study 19881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises with hip internally rotated (n=20)
Number of subjects: 40
Study 19881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises with hip externally rotated (n=20)
Number of subjects: 40
Study 19881323 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program with MRFS System (after four weeks of exercises)
Number of subjects: 40
Study 16792792 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, individually tailored physical rehabilitation programme (8-week duration, including graded, individualized endurance and strength training, three home visits, five follow-up phone calls, and a printed exercise manual)
Number of subjects: 200
Study 16792792 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, individually tailored physical rehabilitation programme
Number of subjects: 200
Study 12762347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone over 24 hours
Number of subjects: 26
Study 11061530 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rGH injections (Group A)
Number of subjects: 34
Study 11061530 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly rGH injections (Group B)
Number of subjects: 34
Study 11061530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 6 months of therapy
Number of subjects: 34
Study 11061530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 12 months of therapy
Number of subjects: 34
Study 11061530 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 healthy subjects)
Number of subjects: 34
Study 8988215 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (nonionic contrast medium)
Number of subjects: 10
Study 8988215 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study 8598549 — intervention group
Group type: COMPARATOR
Intervention: RRR-alpha-tocopheryl acetate (TA) 0 mg/d
Number of subjects: 48
Study 8598549 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 100 mg/d
Number of subjects: 48
Study 8598549 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 200 mg/d
Number of subjects: 48
Study 8598549 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 400 mg/d
Number of subjects: 48
Study 8598549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 48
Study 2573364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36) followed up by a nurse once a month and by a doctor every third month for 12 months.
Number of subjects: 78
Study 2573364 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42) with no intervention.
Number of subjects: 78
Study 2573364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36)
Number of subjects: 78
Study 4555773 — intervention group
Group type: EXPERIMENTAL
Intervention: A2/England/1/1966 vaccine (300 CCA)
Number of subjects: 374
Study 4555773 — intervention group
Group type: EXPERIMENTAL
Intervention: A/equine 2/Miami/1963 vaccine (300 CCA)
Number of subjects: 374
Study 4555773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 30399474 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 500
Study 30399474 — intervention group
Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 500
Study 28450082 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's book
Number of subjects: 282
Study 28450082 — intervention group
Group type: COMPARATOR
Intervention: Brochures
Number of subjects: 282
Study 26049123 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (60 mg/m²) and carboplatin (AUC 2.7) with prophylactic G-CSF (filgrastim) given on day 5 (and if needed on day 6)
Number of subjects: 108
Study 26049123 — intervention group
Group type: COMPARATOR
Intervention: Historical data without routine use of prophylactic G-CSF
Number of subjects: 108
Study 23945031 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (measures both INR variability and control)
Number of subjects: 819
Study 23945031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TIR (< 39%)
Number of subjects: 819
Study 23945031 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B2 (measures variability only)
Number of subjects: 819
Study 21691608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 25
Study 21691608 — intervention group
Group type: COMPARATOR
Intervention: Resilient telescopic crowns
Number of subjects: 25
Study 21691608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 20001678 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 20001678 — intervention group
Group type: COMPARATOR
Intervention: Non-SMBG (control group)
Number of subjects: 0
Study 16769471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone treatment
Number of subjects: 9
Study 12897375 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed TSH levels (untreated)
Number of subjects: 93
Study 12897375 — intervention group
Group type: COMPARATOR
Intervention: Normal TSH
Number of subjects: 93
Study 12897375 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hyperthyroidism
Number of subjects: 93
Study 12897375 — intervention group
Group type: EXPERIMENTAL
Intervention: Subnormal but not suppressed TSH
Number of subjects: 93
Study 12897375 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid patients with positive thyroid antibody titers
Number of subjects: 93
Study 12897375 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 93
Study 10976979 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea Plus tea (5 to 6 cups per day for 5 days)
Number of subjects: 95
Study 10976979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 9129557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-strength grapefruit juice with 60 mg terfenadine
Number of subjects: 12
Study 9129557 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice with 60 mg terfenadine
Number of subjects: 12
Study 9129557 — intervention group
Group type: COMPARATOR
Intervention: Water with 60 mg terfenadine
Number of subjects: 12
Study 9129557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-strength grapefruit juice
Number of subjects: 12
Study 9129557 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice
Number of subjects: 12
Study 8415264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade) in the form of metered dosimeter aerosol
Number of subjects: 40
Study 8415264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2868573 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 60
Study 2868573 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 60
Study 29356576 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Alpha-Lipoic Acid (ALA) per day for 1 month before surgery and for 2 months afterward
Number of subjects: 20
Study 29356576 — intervention group
Group type: COMPARATOR
Intervention: Placebo per day for 1 month before surgery and for 2 months afterward
Number of subjects: 20
Study 27863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning combined strength and endurance training (mE + S)
Number of subjects: 42
Study 27863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening combined strength and endurance training (eE + S)
Number of subjects: 42
Study 27863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning combined strength and endurance training (mS + E)
Number of subjects: 42
Study 27863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening combined strength and endurance training (eS + E)
Number of subjects: 42
Study 27863207 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (mE + S, mS + E, eE + S, eS + E)
Number of subjects: 42
Study 24190902 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring alone
Number of subjects: 145
Study 24190902 — intervention group
Group type: COMPARATOR
Intervention: Combined clinic and ambulatory blood pressure (ABP) measurements
Number of subjects: 145
Study 22267825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with silent brain infarction (SBI)
Number of subjects: 1014
Study 22267825 — intervention group
Group type: COMPARATOR
Intervention: Patients without silent brain infarction (SBI)
Number of subjects: 1014
Study 20635452 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mm thin rod
Number of subjects: 49
Study 20635452 — intervention group
Group type: COMPARATOR
Intervention: 5.5 mm thick rod
Number of subjects: 49
Study 18687828 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-strand repair
Number of subjects: 29
Study 18687828 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-strand repair
Number of subjects: 29
Study 15753789 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT images
Number of subjects: 15
Study 15753789 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected gated SPECT images
Number of subjects: 15
Study 12501944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural arthritis education programme
Number of subjects: 54
Study 12501944 — intervention group
Group type: COMPARATOR
Intervention: Standard arthritis education programme (control group)
Number of subjects: 54
Study 10622650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10622650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegorgotein, 2,000 IU/kg
Number of subjects: 67
Study 10622650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegorgotein, 5,000 IU/kg
Number of subjects: 67
Study 7724304 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion for oligohydramnios in labor
Number of subjects: 42
Study 7724304 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 42
Study 1828550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 10 mg daily (days 12-25)
Number of subjects: 48
Study 1828550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to medroxyprogesterone acetate)
Number of subjects: 48
Study 6313501 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g guar gum
Number of subjects: 10
Study 31380663 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrowers showing greater positive arousal (e.g., excitement) in profile photos
Number of subjects: 13500
Study 31380663 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrowers showing open 'excited' smiles
Number of subjects: 13500
Study 31380663 — intervention group
Group type: COMPARATOR
Intervention: Excited borrowers
Number of subjects: 13500
Study 31094789 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 27
Study 28415937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin saline (50 IU/ml, 3 ml)
Number of subjects: 286
Study 28415937 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (3 ml)
Number of subjects: 286
Study 25733465 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Food Insecurity (CFI)
Number of subjects: 3605
Study 24390887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback (weight, BMI, blood pressure, homeostatic insulin resistance, nuclear magnetic resonance lipoprotein profiles at 2, 4, 7, and 10 months)
Number of subjects: 0
Study 24390887 — intervention group
Group type: COMPARATOR
Intervention: Limited feedback (weight, BMI, and blood pressure at 4 and 10 months)
Number of subjects: 0
Study 22848481 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 160
Study 22848481 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 160
Study 19276983 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alcoholic red wine (8.1±0.9 dl)
Number of subjects: 22
Study 19276983 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized red wine
Number of subjects: 22
Study 19276983 — intervention group
Group type: COMPARATOR
Intervention: Cognac (2.4±0.3 dl)
Number of subjects: 22
Study 17445412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acehytisine Hydrochloride (AHH) 4 mg/kg, iv.
Number of subjects: 201
Study 17445412 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (PRO) 1 mg/kg, iv.
Number of subjects: 201
Study 17445412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acehytisine Hydrochloride (AHH)
Number of subjects: 201
Study 17445412 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (PRO)
Number of subjects: 201
Study 15359921 — intervention group
Group type: EXPERIMENTAL
Intervention: Met-PET scan
Number of subjects: 11
Study 15359921 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination
Number of subjects: 11
Study 15359921 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up MR findings
Number of subjects: 11
Study 11176735 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine hydrochloride alone (drug-alone group)
Number of subjects: 53
Study 11176735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus group lifestyle modification (drug-plus-lifestyle group)
Number of subjects: 53
Study 11176735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus portion-controlled diet (combined treatment group)
Number of subjects: 53
Study 11176735 — intervention group
Group type: COMPARATOR
Intervention: Drug-alone group
Number of subjects: 53
Study 11176735 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-plus-lifestyle and combined treatment groups
Number of subjects: 53
Study 11176735 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study 9608581 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (α2 antagonist)
Number of subjects: 0
Study 9608581 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8140046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg) under fasting conditions
Number of subjects: 24
Study 8140046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg) after a high-fat meal
Number of subjects: 24
Study 8140046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (180 mg) under fasting conditions
Number of subjects: 24
Study 8140046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (180 mg) after a high-fat meal
Number of subjects: 24
Study 3132732 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium ion radiation therapy
Number of subjects: 49
Study 3132732 — intervention group
Group type: COMPARATOR
Intervention: Split-course megavoltage photon irradiation
Number of subjects: 49
Study 29761915 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (TED) 0.05 mg/kg/day
Number of subjects: 14
Study 28405683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder intracavitary hyperthermic perfusion chemotherapy (BHPC)
Number of subjects: 53
Study 28405683 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone
Number of subjects: 53
Study 26244758 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 1408
Study 24011094 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion and substance use
Number of subjects: 179
Study 24011094 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support, care and connection; reducing substance use
Number of subjects: 179
Study 24011094 — intervention group
Group type: COMPARATOR
Intervention: Family conflict, depressive symptoms, delinquency, school enrollment
Number of subjects: 179
Study 20967571 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise support therapy (ST)
Number of subjects: 29
Study 20967571 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (PT)
Number of subjects: 29
Study 18543585 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect measurement of blood loss calculation based on post-operative drop in haemoglobin (Hb) in pregnant women
Number of subjects: 66
Study 18543585 — intervention group
Group type: COMPARATOR
Intervention: Indirect measurement of blood loss calculation based on post-operative drop in haemoglobin (Hb) in non-pregnant women
Number of subjects: 66
Study 16498858 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetirizine‐dinitrate (2.44 mg per nasal cavity) delivered via nasal spray device
Number of subjects: 0
Study 16498858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline lavage before treatment)
Number of subjects: 0
Study 15486848 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 224
Study 10930904 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC400 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 200 mg b.d.)
Number of subjects: 100
Study 10930904 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC800 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 400 mg b.d.)
Number of subjects: 100
Study 10930904 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC400
Number of subjects: 100
Study 10930904 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC800
Number of subjects: 100
Study 9032502 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training (IT) at heart rate corresponding to gas exchange threshold (GET)
Number of subjects: 24
Study 9032502 — intervention group
Group type: COMPARATOR
Intervention: Standardized training (ST) at heart rate corresponding to 50% of maximal heart rate reserve
Number of subjects: 24
Study 8519379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin
Number of subjects: 10
Study 8519379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled kallidin
Number of subjects: 10
Study 8519379 — intervention group
Group type: COMPARATOR
Intervention: Inhaled [desArg9]-bradykinin
Number of subjects: 10
Study 8519379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled kallidin after bradykinin challenge
Number of subjects: 10
Study 8519379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin after kallidin challenge
Number of subjects: 10
Study 8519379 — intervention group
Group type: COMPARATOR
Intervention: Repeated exposures with inhaled [desArg9]-bradykinin
Number of subjects: 10
Study 2958234 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial cream for glass fibre itching
Number of subjects: 0
Study 2958234 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone spray
Number of subjects: 0
Study 2958234 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient cream
Number of subjects: 0
Study 2958234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty ointment
Number of subjects: 0
Study 2958234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream-ointment
Number of subjects: 0